AU2005287934B2 - Urokinase plasminogen activator receptor targeted contrast agent - Google Patents

Urokinase plasminogen activator receptor targeted contrast agent Download PDF

Info

Publication number
AU2005287934B2
AU2005287934B2 AU2005287934A AU2005287934A AU2005287934B2 AU 2005287934 B2 AU2005287934 B2 AU 2005287934B2 AU 2005287934 A AU2005287934 A AU 2005287934A AU 2005287934 A AU2005287934 A AU 2005287934A AU 2005287934 B2 AU2005287934 B2 AU 2005287934B2
Authority
AU
Australia
Prior art keywords
imaging agent
imaging
moiety
ser
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005287934A
Other languages
English (en)
Other versions
AU2005287934A1 (en
Inventor
Bente E. Arbo
Alan Cuthbertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of AU2005287934A1 publication Critical patent/AU2005287934A1/en
Application granted granted Critical
Publication of AU2005287934B2 publication Critical patent/AU2005287934B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2005287934A 2004-09-29 2005-09-28 Urokinase plasminogen activator receptor targeted contrast agent Ceased AU2005287934B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20044139 2004-09-29
NO20044139 2004-09-29
PCT/NO2005/000362 WO2006036071A2 (en) 2004-09-29 2005-09-28 Urokinase plasminogen activator receptor targeted contrast agent

Publications (2)

Publication Number Publication Date
AU2005287934A1 AU2005287934A1 (en) 2006-04-06
AU2005287934B2 true AU2005287934B2 (en) 2009-03-26

Family

ID=35930012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005287934A Ceased AU2005287934B2 (en) 2004-09-29 2005-09-28 Urokinase plasminogen activator receptor targeted contrast agent

Country Status (11)

Country Link
US (1) US8568689B1 (enExample)
EP (1) EP1796733A2 (enExample)
JP (1) JP5122962B2 (enExample)
KR (1) KR101248350B1 (enExample)
CN (1) CN101065152A (enExample)
AU (1) AU2005287934B2 (enExample)
BR (1) BRPI0516168A (enExample)
CA (1) CA2580464A1 (enExample)
MX (1) MX2007003750A (enExample)
RU (1) RU2394837C2 (enExample)
WO (1) WO2006036071A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190068A1 (en) * 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
DK2598175T3 (da) * 2010-07-27 2020-08-03 Serac Healthcare Ltd Radiofarmaceutiske sammensætninger
JP2015532636A (ja) * 2012-05-08 2015-11-12 リグスホスピタレト 部位特異的ｕＰＡＲ標的化のための１７７−Ｌｕ標識ペプチド
US9884131B2 (en) * 2012-12-03 2018-02-06 Curasight Aps Positron emitting radionuclide labeled peptides for human uPAR PET imaging
US20210138090A1 (en) * 2014-09-17 2021-05-13 Fluoguide A/S uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
AU2015317444B2 (en) * 2014-09-17 2020-07-16 Fluoguide A/S uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
RU2720976C2 (ru) * 2015-06-03 2020-05-15 Сюржимаб С.А.С. Флуоресцентные конъюгаты и их применение для диагностики опухоли
US11970554B2 (en) 2018-03-01 2024-04-30 Tonix Pharmaceuticals Holding Corp. Labeled oxytocin and method of manufacture and use
WO2021009219A1 (en) * 2019-07-16 2021-01-21 Fluoguide A/S A receptor-targeting conjugate with an effective pharmacokinetic profile
BR112022000164A2 (pt) * 2019-07-16 2022-04-12 Fluoguide As Conjugado de peptídeo direcionado a receptor de ativador de uroquinase-plasminogênio, composição farmacêutica, métodos para imageamento óptico e para detecção de uma doença, uso do conjugado de peptídeo ou da composição farmacêutica, e, kit de peças para a preparação de uma dosagem unitária
CN117412777A (zh) * 2020-12-01 2024-01-16 库拉赛特股份公司 尿激酶纤溶酶原活化剂受体靶向的放射性标记的肽缀合物
EP4277666A1 (en) * 2021-01-15 2023-11-22 Fluoguide A/S A upar (urokinase plasminogen activator receptor)-targeting conjugate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025410A2 (en) * 1999-10-01 2001-04-12 Angstrom Pharmaceuticals, Inc. DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120765A (en) * 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
GB9705521D0 (en) 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
AR020101A1 (es) * 1998-07-01 2002-04-10 Cancerforskingsfonden Af 1989 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
US6896870B1 (en) * 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
US7763234B2 (en) 2004-03-04 2010-07-27 Ge Healthcare As Pharmaceutical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025410A2 (en) * 1999-10-01 2001-04-12 Angstrom Pharmaceuticals, Inc. DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ploug M et al., 1998, Biochemistry, Vol 37, pp 3612-3622 *

Also Published As

Publication number Publication date
KR20070083604A (ko) 2007-08-24
AU2005287934A1 (en) 2006-04-06
JP2008514588A (ja) 2008-05-08
WO2006036071A3 (en) 2007-02-15
MX2007003750A (es) 2007-11-07
JP5122962B2 (ja) 2013-01-16
KR101248350B1 (ko) 2013-04-01
RU2007111467A (ru) 2008-11-10
EP1796733A2 (en) 2007-06-20
CA2580464A1 (en) 2006-04-06
BRPI0516168A (pt) 2008-08-26
US8568689B1 (en) 2013-10-29
RU2394837C2 (ru) 2010-07-20
CN101065152A (zh) 2007-10-31
WO2006036071A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
AU2003299957B2 (en) Improved gastrin releasing peptide compounds
CN103533963B (zh) 用通过nota络合的[18]氟化铝标记的her2结合肽
AU2005287934B2 (en) Urokinase plasminogen activator receptor targeted contrast agent
US9119885B2 (en) RGD-containing peptidomimetics and uses thereof
JP7667765B2 (ja) がんイメージング及びがん放射線治療のための組成物及び方法
CN103402550B (zh) 用含有18f的有机硅化合物标记的her2结合肽
US20100015058A1 (en) Radiolabeled bbn-rgd heterodimers for cancer targeting
EP3412303A1 (en) Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
JP5116480B2 (ja) 造影剤
US20070134155A1 (en) Pharmaceutical compounds
AU2005254915B2 (en) Peptide-based compounds
WO2005084715A2 (en) Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
KR20230152698A (ko) 진단 및 요법을 위한 개선된 콜레시스토키닌-2 수용체(cck2r) 표적화
AU2004314112A1 (en) Improved gastrin releasing peptide compounds
HK1193987A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
HK1191244A (en) Her2 binding peptides labelled with a 18f - containing organosilicon compound

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired